In this brief presentation, neurosurgeon Steven Brem, MD, reviews Novo-TTF (tumor-treating fields), a modality for glioblastoma that involves the induction of a low intensity electric field within the brain to disrupt cell division during mitosis. Dr. Brem reports on the key study findings, and the known advantages of TTF, which include a significant prolongation of progression-free and overall survival, improved quality of life, absence of cognitive decline and seizures, and few side effects.
Related Links
Published
September 20, 2016
Created by
BROADCASTMED